SEK 49 million to EMPE Diagnostics with a focus on rapid diagnosis of tuberculosis
EMPE Diagnostics, which has developed rapid tests for diagnosing and determining resistance to tuberculosis, the world’s deadliest infectious disease, has recently completed an issue of SEK 23.5 million with Sciety and also received a grant of approximately SEK 25 million from EU Horizon 2020. The capital will go towards completing the company’s production facility and for sale. For more details,
Andreas Lindblom, CEO of Sciety comments:
The need for rapid diagnostics in pandemics has never been more clear. In Sweden, we have been spared from tuberculosis for a long time, but the ongoing corona pandemic has really shown how important is rapid diagnostics. The tuberculosis pandemic kills approximately 1.5 million people a year, and more effective diagnostic solutions can make a big difference here. It is therefore pleasing that EMPE has now secured close to SEK 50 million for the wider market establishment.
Sciety is the Nordic region’s leading investor network in life science and digital health. We combine experience from life science and finance to select prominent companies in the industry. The network includes venture capital companies, family offices and business angels. Sciety’s vision is for life science innovations to reach their full potential.